Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies

Transplantation

Volumn 81, Issue 7, 2006, Pages 1049-1057

  Appel III, James Z ^a   Hartwig, Matthew G ^a   Cantu III, Edward ^a   Palmer, Scott M ^a   Reinsmoen, Nancy L ^a   Davis, R Duane ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Crossmatch; Flow cytometry; HLA specific antibodies; Lung transplantation; Panel reactive antibodies

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BRONCHIOLITIS OBLITERANS; FEMALE; GRAFT FAILURE; HLA SYSTEM; HOSPITAL ADMISSION; HUMAN; HYPERACUTE GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRTUAL REALITY;

ADULT; ANTIBODIES; ANTIBODY SPECIFICITY; BLOOD GROUPING AND CROSSMATCHING; BRONCHIOLITIS OBLITERANS; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HLA ANTIGENS; HUMANS; INCIDENCE; INTRAOPERATIVE PERIOD; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NORTH CAROLINA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; WAITING LISTS;

EID: 33646344730     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000204046.89396.c5     Document Type: Article

References (42)

1. Williams GM, Hume DM, Hudson RP Jr., et al. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279(12): 611-618.
2. Weil R 3rd, Clarke DR, Iwaki Y, et al. Hyperacute rejection of a transplanted human heart. Transplantation 1981; 32(1): 71-72.
3. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49(1): 85-91.
4. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989; 8(6): 430-43.
5. Jeannet M, Pinn VW, Flax MH, et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282(3): 111-117.
6. Hess ML, Hastillo A, Mohanakumar T, et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983; 68(3 Pt 2):I94-I101.
7. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110(2): 559-562.
8. Bittner HB, Dunitz J, Hertz M, et al. Hyperacute rejection in single lung transplantation-case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation 2001; 71(5): 649-651.
9. Scornik JC, Zander DS, Baz MA, et al. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry. Transplantation 1999; 68(10): 1542-1546.
10. Bund M, Struber M, Heine J, et al. Effect of lung allograft ischaemia duration on postreperfusion graft function and postoperative course. Thorac Cardiovasc Surg 1998; 46(2): 93-96.
11. Appel J III, Davis R. The evolution of lung transplantation - a clinical update. Transplant Rev 2004; 18(1): 20-37.
12. Kerman RH, Susskind B, Ruth J, et al. Can an immunologically, non-reactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Transplantation 1998; 66(12): 1833-1834.
13. Matas AJ, Sutherland DE. Kidney transplantation without a final cross-match. Transplantation 1998; 66(12): 1835-1836.
14. Taylor CJ, Smith SI, Morgan CH, et al. Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time. Transplantation 2000; 69(5): 719-723.
15. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 59(5): 313-322.
16. Herczyk WF, Burgess BO, Tuttle-Newhall J, Reinsmoen NL.. Identification of unacceptable antigens using flow cytometric bead techniques to significantly reduce unnecessary crossmatches for sensitive patients. Hum Immunol 2003; 64(10 Suppl): S35.
17. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69(5): 1520-1524.
18. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74(6): 799-804.
19. Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124(5): 1689-1693.
20. Hartwig M, Lin S, Simsir S, Davis R. Lung Transplantation. In: Kuo PC DR, editor. Comprehensive Atlas of Organ Transplantation. Philadelphia: Lippincott, Williams and Wilkins; 2004.
21. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5(1): 131-138.
22. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15(1 Pt 1):1-15.
23. Reinsmoen N, Mohler K, Palmer S, et al. Correlation of donor antigen-specific class II antibodies with chronic rejection. In press.
24. Smith JD, Danskine AJ, Rose ML, Yacoub MH. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992; 53(6): 1358-1362.
25. George JF, Kirklin JK, Shroyer TW, et al. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. J Heart Lung Transplant 1995; 14(5): 856-864.
26. Suciu-Foca N, Ho E, King DW, et al. Soluble HLA and anti-idiotypic antibodies in transplantation: modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients. Transplant Proc 1991; 23(1 Pt 1): 295-296.
27. Schonemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998; 65(11): 1519-1523.
28. Martin STC. The immunologically sensitized renal transplant recipient: the impact of advances in technology on organ allocation and transplant outcome. Transplant Rev 1999; 13(1): 40.
29. Chapman JR, Taylor CJ, Ting A, Morris PJ. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 1986; 42(6): 608-613.
30. Roelen DL, van Bree J, Witvliet MD, et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation 1994; 57(9): 1388-1392.
31. Herczyk W. ASHI Quarterly 2003; 27(1).
32. Tambur AR, Bray RA, Takemoto SK, et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000; 70(7): 1055-1059.
33. Magro CM, Deng A, Pope-Harman A, et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002; 74(9): 1273-1280.
34. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76(4): 631-636.
35. Burgess BO, Palmer S, Russell SD, et al. Impact of plasmapheresis/IvIg therapies on antibody levels and graft outcome in heart and lung recipients. Hum Immunol 2003; 64(10 Suppl): S110.
36. Mares DC, Heidler KM, Smith GN, et al. Type V collagen modulates alloantigen-induced pathology and immunology in the lung. Am J Respir Cell Mol Biol 2000; 23(1): 62-70.
37. Magro CM, Klinger DM, Adams PW, et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003; 3(10): 1264-1272.
38. Appel J III, Hartwig MG, Davis RD, Reinsmoen NL. Utility of Peritransplant and Rescue IVIG and Extracorporeal Immunoadsorption in Lung Transplant Recipients Sensitized to HLA Antigens. Hum Immunol 2005; 66(4): 378-386.
39. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75(9): 1490-1495.
40. Appel J III, Hartwig MG, Cantu E, et al. Differences in Survival and De Novo Anti-donor Antibody Development Among Lung Transplant Recipients Presensitized to Third Party Class I and Class II HLA Antigens J Heart Lung Transplant 2005; 24(2S): S93.
41. Soares MP, Lin Y, Sato K, et al. Accommodation. Immunol Today 1999; 20 (10): 434-437.
42. Hadjiliadis D, Davis RD, Palmer SM. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? Chest 2002; 122(4): 1168-1175.